Since its IPO, BioNTech shares have been rising in value; though the company does not pay any dividends to its shareholders, its popularity is still attracting investors. The company's rising demand for its COVID-19 vaccine and the prospects of upcoming vaccines and treatments for other diseases like melanoma and solid tumors shows excellent potential in the future.